Physician profile
Raphael Adam Morris
NPI 1801811104
$8,286.14
in general payments reported to CMS, 2019-2025
26 companies · $721 in 2025
The $721 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,731 · 2020: $1,759 · 2021: $705 · 2022: $363 · 2023: $722 · 2024: $285 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.04 |
| Education | $116.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,613.52 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $1,069.11 | 2019-2022 | |
| Neuronetics, INC. | $930.84 | 2019-2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $767.93 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $704.58 | 2020-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $586.87 | 2019-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $551.20 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $474.57 | 2019-2025 | Trintellix |
| Allergan, INC. | $313.55 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $254.08 | 2019-2025 | Austedo Xr |
| Shire North American Group INC | $187.05 | 2019 | |
| Ironshore Pharmaceuticals INC. | $115.72 | 2019-2022 | |
| Bausch Health US, LLC | $112.98 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $108.65 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.10 | 2020-2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $67.69 | 2019-2020 | |
| Abbvie INC. | $67.21 | 2021-2023 | |
| Vertical Pharmaceuticals, LLC | $65.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $55.81 | 2019 | |
| Idorsia Pharmaceuticals US INC | $40.37 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $39.86 | 2019 | |
| Amgen INC. | $18.96 | 2020 | |
| Merck Sharp & Dohme LLC | $18.17 | 2019 | |
| Lilly USA, LLC | $17.77 | 2019 | |
| Adlon Therapeutics L.P. | $15.71 | 2020 | |
| Brainsway USA INC | $10.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.